{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:59:05Z","timestamp":1762498745548,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.euf.2023.01.010","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T07:45:07Z","timestamp":1674287107000},"page":"405-406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intermittent Hormonal Therapy in Biochemical Recurrence of Prostate Cancer Is Worth Considering Because of Mitigation of Cardiovascular Events and Reduction of Other Effects"],"prefix":"10.1016","volume":"9","author":[{"given":"Daniel H.","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul R.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2023.01.010_b0005","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(17)30426-6","article-title":"Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01\u201303 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"18","author":"Duchesne","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2023.01.010_b0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01\u201303 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2023.01.010_b0015","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1161\/ATVBAHA.119.313046","article-title":"Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses","volume":"40","author":"Hu","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.euf.2023.01.010_b0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2023.01.010_b0025","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaoncol.2015.2895","article-title":"Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"1","author":"Magnan","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2023.01.010_b0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2490-14-9","article-title":"Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis","volume":"14","author":"Engel Ayer Botrel","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.euf.2023.01.010_b0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/pcan.2016.35","article-title":"A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients","volume":"19","author":"Jin","year":"2016","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2023.01.010_b0040","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2023.01.010_b0045","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl 7","key":"10.1016\/j.euf.2023.01.010_b0050","doi-asserted-by":"crossref","first-page":"S1428","DOI":"10.1016\/j.annonc.2022.08.066","article-title":"LBA63 PRESTO: a phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)","volume":"33","author":"Aggarwal","year":"2022","journal-title":"Ann Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:54:17Z","timestamp":1762498457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456923000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2405456923000263"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2023.01.010","relation":{},"ISSN":["2405-4569"],"issn-type":[{"type":"print","value":"2405-4569"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermittent Hormonal Therapy in Biochemical Recurrence of Prostate Cancer Is Worth Considering Because of Mitigation of Cardiovascular Events and Reduction of Other Effects","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2023.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}